NURO News and Press, NeuroMetrix Inc. From 10/15/20

WOBURN, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the market on October 22, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on Octobe...

The global autonomous vehicle [AV] market demand is expected to reach 4.2 million units by 2030, expanding at a CAGR of 63.1% from 2020 to 2030. AV revenues will be spread across several areas such as the software developers, hardware developers, the EV companies selling EV fleets, an...

WOBURN, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App, now available for download from the Apple App store. Quell is a wearable, transcutaneous electrical nerve stimulation (TENS) device for knee, foot ...

NeuroMetrix (NURO) patents 'Apparatus and Method for Relieving Pain Using Transcutaneous Electrical Nerve Stimulation.'The patent covers core Quell technology that regulates electrical stimulation based on the device orientation.“We are continually working to make Quell smart...

WOBURN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No. 10,780,269 titled “Apparatus and Method for Relieving Pain Using Transcutaneous Elec...

WOBURN, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be held September 11 - 13.  PAINWeek is the preferred resource in the U.S. for front...

WOBURN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the severity of diabetic peripheral neuropathy (DPN).  DPNCheck is a widely used point-of-care test...

WOBURN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH-funded, multi-site randomized controlled trial (RCT) of the efficacy of transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced ...

WOBURN, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) published an infographic on chronic knee pain ( available here ) and provided an update on how Quell technology addresses knee pain. One-quarter of U.S. adults suffer from frequent knee pain, which d...

NeuroMetrix, Inc. (NURO) Q2 2020 Earnings Conference Call July 23, 2020, 8:00 am ET Company Participants Thomas Higgins - SVP & CFO Shai Gozani - President & CEO Conference Call Participants Presentation Operator Good morning and welcome to the NeuroMetrix Sec...